Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Summary

The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.

Timeline

Start

2019-01-31

Primary completion

2019-07-03

Completion

2019-07-03

Drugs

Indications